BioSpace News Archive

The hormone replacement therapy market is foreseen to expand at a significant pace with sales of products crossing US$ 12,000 Mn by 2019 end

Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.6 million, or $0.37 per diluted share, on net sales of $36.5 million for the quarter ended September 30, 2018

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Kim Blickenstaff, President and Chief Executive Officer and Leigh Vosseller, EVP and Chief Financial Officer, will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 in Scottsdale, AZ at 12:20pm Eastern Time (9:20am Pacific).

Conference Call – 8:30am Thursday, November 15th

At the first China International Import Expo, Sanofi, the world’s leading healthcare company, said during the China Health Road Symposium, that with Innovation, Partnership and Commitment as the three key words, it will strive to introduce the innovative drugs and vaccines exhibited at the import expo to China as early as possible.

Strategic combination will strengthen SVB’s position as the leading financial services provider to Healthcare and Life Science Companies

Advancement of SYNB1891, the first Synthetic Biotic™ immuno-oncology candidate to enable Investigational New Drug Application (IND) filing in 2H 2019

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2018 (“Q1 FY 2019”).

Defined Health, a leading business development strategy consulting firm with a particular focus in early stage biotech announced today that it has changed its name to Cello Health BioConsulting.

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, today announces its presentation of new data regarding its First-In-Class GM102 antibody at two upcoming conferences.